Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

NCT07064330 · clinicaltrials.gov ↗

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cutaneous Squamous Cell Carcinoma (CSCC)

Interventions

DRUG: Cemiplimab

Sponsor

Instituto de Investigación Biomédica de Salamanca

Collaborators

[object Object]
[object Object]
[object Object]